Boston Scientific buys gene therapy company in series of acquisitions
This article was originally published in Clinica
Two weeks after announcing its intention to pay $2.1 billion for catheter manufacturer, Schneider Worldwide, Boston Scientific has agreed to buy the development-stage company CardioGene Therapeutics, for an undisclosed amount.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.